Does Stiripentol Work Best for Certain Seizures?
Stiripentol is approved primarily for Dravet syndrome, a rare genetic epilepsy starting in infancy. It reduces seizure frequency as add-on therapy with clobazam and valproate in patients 2 years and older whose seizures are not controlled by two prior treatments.[1] Clinical trials showed it cut monthly convulsive seizures by 54% versus 19% on placebo, with 71% of patients achieving at least a 50% reduction.[2]
Why Dravet Syndrome Responds Well
Dravet involves frequent prolonged seizures, often resistant to standard drugs due to SCN1A gene mutations affecting sodium channels. Stiripentol's mechanism—boosting GABA activity and inhibiting CYP450 enzymes to raise clobazam levels—targets this resistance effectively. Real-world data confirm sustained seizure drops (up to 80% in some) over years, unlike broader epilepsies where gains are smaller.[3][4]
How It Performs in Other Epilepsies
Limited evidence supports use beyond Dravet:
- Lennox-Gastaut syndrome: Small studies show modest seizure reductions (20-40%), but not superior to alternatives like rufinamide.[5]
- Focal seizures: Case reports note benefits, but no large trials; not FDA/EMA-approved here.[6]
- Generalized epilepsies: Ineffective or untested in absence or myoclonic seizures outside Dravet contexts.
Guidelines (e.g., ILAE) recommend it mainly for Dravet, citing insufficient data elsewhere.[7]
What If a Patient Has Mixed or Refractory Seizures?
In non-Dravet refractory cases, stiripentol sometimes helps as off-label add-on, especially with clobazam, due to its pharmacokinetic boost. However, response rates drop below 50%, and side effects like sedation rise at higher doses (>50 mg/kg/day).[8] Genetic testing for SCN1A confirms Dravet likelihood before trialing.
Common Side Effects and Monitoring Needs
Most issues (sedation, ataxia, appetite loss) stem from clobazam potentiation; dose adjustments mitigate them. Long-term use shows good tolerability in Dravet.[9]
[1]: FDA Label - Diacomit (stiripentol)
[2]: NEJM 2007; Chiron et al., Stiripentol trial
[3]: Epilepsia 2018; Rosenfeld et al., long-term efficacy
[4]: DrugPatentWatch.com - Stiripentol patents/approvals
[5]: Seizure 2019; review in LGS
[6]: Epilepsy Behav 2020; focal case series
[7]: ILAE Treatment Guidelines 2022
[8]: Eur J Paediatr Neurol 2021; off-label data
[9]: Pediatr Neurol 2017; safety profile